Lipoprotein(a)

Lipoprotein(a) is an LDL-like particle with an added apolipoprotein(a) tail. Its level is roughly 80–90% genetically determined and stays fairly stable through life, so a single measurement usually suffices.

Elevated Lp(a) is an independent, causal risk factor for heart attack, stroke, and calcific aortic valve disease. Because it is inherited and common (affecting perhaps 1 in 5 people), measuring it once identifies risk that standard panels miss.

1. 1

   FoundationCardiovascular HealthThe best place to understand what actually prevents heart disease.
2. 2

   ConditionAtherosclerotic Cardiovascular DiseaseThe disease behind most heart attacks and strokes
3. 3

   Body SystemCardiovascularHeart function, blood pressure, and circulatory health.
4. 4

   BiomarkerApolipoprotein BThe atherogenic particle-count marker

1. Measure it
2. Understand your result
3. See what raises and lowers it
4. Apply evidence-based interventions
5. Recheck on your review cadence

An orientation to how this topic is typically approached — not medical advice.

A high Lp(a) raises cardiovascular risk on top of LDL and should intensify attention to every other modifiable factor. Crucially, lifestyle changes do not meaningfully lower it — the response is to control overall risk aggressively.

• One-time blood test
• Best reported in nmol/L (particle number)

Genetic and epidemiologic evidence firmly establishes Lp(a) as causal for cardiovascular and aortic-valve disease. Outcome trials of Lp(a)-lowering therapies are ongoing; no lifestyle intervention meaningfully changes it.

• EAS Consensus Statement on Lipoprotein(a)
• 2018 ACC/AHA Cholesterol Guideline
• 2022 EAS updated Lp(a) consensus

Sources are named authoritative guidelines and scientific bodies. Biomarker pages present established clinical context; calibrated evidence verdicts on specific interventions live in the linked Signal Records.